These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 19293927

  • 1. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
    Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J.
    PLoS One; 2009; 4(3):e4881. PubMed ID: 19293927
    [Abstract] [Full Text] [Related]

  • 2. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
    Hung CM, Lin YC, Liu LC, Kuo SC, Ho CT, Way TD.
    Chem Biol Interact; 2016 Dec 25; 260():1-12. PubMed ID: 27769712
    [Abstract] [Full Text] [Related]

  • 3. BF12, a Novel Benzofuran, Exhibits Antitumor Activity by Inhibiting Microtubules and the PI3K/Akt/mTOR Signaling Pathway in Human Cervical Cancer Cells.
    Gao Y, Ma C, Feng X, Liu Y, Haimiti X.
    Chem Biodivers; 2020 Mar 25; 17(3):e1900622. PubMed ID: 31951313
    [Abstract] [Full Text] [Related]

  • 4. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway.
    Li X, Tang Y, Yu F, Sun Y, Huang F, Chen Y, Yang Z, Ding G.
    Mar Drugs; 2018 Sep 11; 16(9):. PubMed ID: 30208576
    [Abstract] [Full Text] [Related]

  • 6. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W, Stachura P, Xu HC, Umesh Ganesh N, Cox F, Wang R, Lang KS, Gopalakrishnan J, Häussinger D, Homey B, Lang PA, Pandyra AA.
    J Exp Clin Cancer Res; 2020 Feb 21; 39(1):38. PubMed ID: 32085796
    [Abstract] [Full Text] [Related]

  • 7. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
    Kim SM, Park JH, Kim KD, Nam D, Shim BS, Kim SH, Ahn KS, Choi SH, Ahn KS.
    Phytother Res; 2014 Mar 21; 28(3):423-31. PubMed ID: 23686889
    [Abstract] [Full Text] [Related]

  • 8. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y, Li L, Huang M, Duan C, Zhang L, Chen J.
    Cell Signal; 2014 Dec 21; 26(12):2782-92. PubMed ID: 25193113
    [Abstract] [Full Text] [Related]

  • 9. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH.
    Am J Physiol Cell Physiol; 2004 Aug 21; 287(2):C281-91. PubMed ID: 15028555
    [Abstract] [Full Text] [Related]

  • 10. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.
    Mol Cancer Ther; 2009 May 21; 8(5):1157-68. PubMed ID: 19417153
    [Abstract] [Full Text] [Related]

  • 11. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.
    Int J Oncol; 2010 Oct 21; 37(4):1023-30. PubMed ID: 20811725
    [Abstract] [Full Text] [Related]

  • 12. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhao L, Zhang J, Fan Y, Li Y.
    Med Sci Monit; 2019 Oct 21; 25():7864-7871. PubMed ID: 31631173
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition.
    Li SS, Chen JJ, Zhang MM, Wang WX, Zhang WY, Ma C.
    Eur J Med Chem; 2024 May 05; 271():116425. PubMed ID: 38636129
    [Abstract] [Full Text] [Related]

  • 14. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ, Cayrefourcq L, Haider MT, Hinz N, Pantel K, Alix-Panabières C, Jücker M.
    Cells; 2020 Sep 20; 9(9):. PubMed ID: 32962206
    [Abstract] [Full Text] [Related]

  • 15. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P, Hu W, Liu C, Li L.
    Arch Biochem Biophys; 2020 Aug 15; 689():108461. PubMed ID: 32531316
    [Abstract] [Full Text] [Related]

  • 16. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Sun H, Yin M, Qian W, Yin H.
    Med Sci Monit; 2018 Sep 05; 24():6178-6186. PubMed ID: 30182951
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological evaluation of imidazo[1,5-a]pyridine-benzimidazole hybrids as inhibitors of both tubulin polymerization and PI3K/Akt pathway.
    Kamal A, Rao AV, Nayak VL, Reddy NV, Swapna K, Ramakrishna G, Alvala M.
    Org Biomol Chem; 2014 Dec 28; 12(48):9864-80. PubMed ID: 25354805
    [Abstract] [Full Text] [Related]

  • 18. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):830-8. PubMed ID: 20522531
    [Abstract] [Full Text] [Related]

  • 19. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
    Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J.
    J Pharmacol Exp Ther; 2005 Sep 01; 314(3):1134-43. PubMed ID: 15923340
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
    Zhang H, Jiang H, Zhang H, Liu J, Hu X, Chen L.
    Eur J Pharmacol; 2019 Sep 05; 858():172477. PubMed ID: 31228450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.